Treatment of norovirus infections: Moving antivirals from the bench to the bedside

Antiviral Research

Volumn 105, Issue 1, 2014, Pages 80-91

  Kaufman, Stuart S ^a   Green, Kim Y ^b   Korba, Brent E ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Antiviral; Diarrhea; Drug treatment; Immunocompromised; Norovirus; Transplant

Indexed keywords

ANTIVIRUS AGENT; MONOCLONAL ANTIBODY; NUCLEOSIDE ANALOG; PROTEINASE INHIBITOR; RNA DIRECTED RNA POLYMERASE INHIBITOR; 2' METHYLCYTIDINE; ALPHA INTERFERON; AZAURIDINE; CHYMOSTATIN; FAVIPIRAVIR; HUMAN INTERFERON; NF 203; NITAZOXANIDE; NOROVIRUS VACCINE; PLACEBO; RIBAVIRIN; RNA VACCINE; SIMVASTATIN; SURAMIN; THIOURIDINE; UNCLASSIFIED DRUG; BIOLOGICAL MARKER;

ACUTE GASTROENTERITIS; ANTIVIRAL THERAPY; DISEASE SEVERITY; DRUG EFFICACY; DRUG MONITORING; EPIDEMIC; HIGH RISK POPULATION; HOSPITALIZATION; HUMAN; IMMUNOCOMPROMISED PATIENT; NONHUMAN; NOROVIRUS; NOROVIRUS INFECTION; NURSING HOME; PATIENT CARE; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; STUDY DESIGN; UNITED STATES; VIRUS TRANSMISSION; ADAPTIVE IMMUNITY; CRYSTAL STRUCTURE; DOUBLE BLIND PROCEDURE; DRUG DEVELOPMENT; FLUID RESUSCITATION; IC 50; IMMUNOCOMPETENCE; INCUBATION TIME; INFECTION CONTROL; INFECTION SENSITIVITY; INFLUENZA VACCINATION; MORBIDITY; MORTALITY; RANDOMIZED CONTROLLED TRIAL (TOPIC); RNA VIRUS INFECTION; UNFOLDED PROTEIN RESPONSE; VIRAL CLEARANCE; VIRUS ATTACHMENT; VIRUS CELL INTERACTION; VIRUS NEUTRALIZATION; VIRUS REPLICATION; VIRUS SHEDDING; VIRUS VIRULENCE; CALICIVIRIDAE INFECTIONS; CLINICAL TRIAL (TOPIC); DRUG EFFECTS; DRUG SCREENING; EPIDEMIOLOGY; HEALTH; ISOLATION AND PURIFICATION; PATHOLOGY; PROCEDURES;

ANTIVIRAL AGENTS; BIOLOGICAL MARKERS; CALICIVIRIDAE INFECTIONS; CLINICAL TRIALS AS TOPIC; DRUG EVALUATION, PRECLINICAL; DRUG MONITORING; GLOBAL HEALTH; HUMANS; IMMUNOCOMPROMISED HOST; NOROVIRUS; UNITED STATES;

EID: 84897841130     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2014.02.012     Document Type: Review

References (106)

1. I. Alam, J.H. Lee, K.J. Cho, K.R. Han, J.M. Yang, M.S. Chung, and K.H. Kim Crystal structures of murine norovirus-1 RNA-dependent RNA polymerase in complex with 2-thiouridine or ribavirin Virology 426 2012 143 151
2. N.H. Alam, H. Ashraf, S.A. Sarker, M. Olesen, J. Troup, M.A. Salam, N. Gyr, and R. Meier Efficacy of partially hydrolyzed guar gum-added oral rehydration solution in the treatment of severe cholera in adults Digestion 78 2008 24 29
3. M.K. Arness, B.H. Feighner, M.L. Canham, D.N. Taylor, S.S. Monroe, T.J. Cieslak, E.L. Hoedebecke, C.S. Polyak, J.C. Cuthie, R.L. Fankhauser, C.D. Humphrey, T.L. Barker, C.D. Jenkins, and D.R. Skillman Norwalk-like viral gastroenteritis outbreak in U.S. Army trainees Emerg. Infect Dis. 6 2000 204 207
4. R.L. Atmar, and M.K. Estes The epidemiologic and clinical importance of norovirus infection Gastroenterol. Clin. North Am. 35 2006 275 290
5. G. Belliot, S.V. Sosnovtsev, K.-O. Chang, V. Babu, U. Uche, J.J. Arnold, C.E. Cameron, and K.Y. Green Norovirus proteinase-polymerase and polymerase are both active forms of RNA-dependent RNA polymerase J. Virol. 79 2005 2393 2403
6. H. Bernard, M. Höhne, S. Niendorf, D. Altmann, and K. Stark Epidemiology of norovirus gastroenteritis in Germany 2001-2009: eight seasons of routine surveillance Epidemiol. Infect. 142 2014 63 74
7. K. Bok, and K.Y. Green Norovirus gastroenteritis in immunocompromised patients N. Engl. J. Med. 367 2012 2126 2132
8. K. Bok, G.I. Parra, T. Mitra, E. Abente, C.K. Shaver, D. Boon, R. Engle, C. Yu, A.Z. Kapikian, S.V. Sosnovtsev, R.H. Purcell, and K.Y. Green Chimpanzees as an animal model for human norovirus infection and vaccine development Proc. Natl. Acad. Sci. U.S.A. 108 2011 325 330
9. A.A. Boudreault, H. Xie, W. Leisenring, J. Englund, L. Corey, and M. Boeckh Impact of corticosteroid treatment and antiviral therapy on clinical outcomes in hematopoietic cell transplant patients infected with influenza virus Biol. Blood Marrow Transplant. 17 2011 979 986
10. J.S. Bresee, R. Marcus, R.A. Venezia, W.E. Keene, D. Morse, M. Thanassi, P. Brunett, S. Bulens, R.S. Beard, L.A. Dauphin, L. Slutsker, C. Bopp, M. Eberhard, A. Hall, J. Vinje, S.S. Monroe, and R.I. Glass The etiology of severe acute gastroenteritis among adults visiting emergency departments in the United States J. Infect. Dis. 205 2012 1374 1381
11. K.-O. Chang Role of cholesterol pathways in norovirus replication J. Virol. 83 2009 8587 8595
12. K.O. Chang, and D.W. George Interferons and ribavirin effectively inhibit Norwalk virus replication in replicon-bearing cells J. Virol. 81 2007 12111 12118
13. K.O. Chang, S.V. Sosnovtsev, G. Belliot, A.D. King, and K.Y. Green Stable expression of a Norwalk virus RNA replicon in a human hepatoma cell line Virology 353 2006 463 473
14. K.-O. Chang, D. Takahashi, O. Prakash, and Y. Kim Characterization and inhibition of Norovirus proteases of genogroups I and II using a florescence resonance energy transfer assay Virology 423 2012 125 133
15. S. Cheetham, M. Souza, T. Meulia, S. Grimes, M.G. Han, and L.J. Saif Pathogenesis of a genogroup II human norovirus in gnotobiotic pigs J. Virol. 80 2006 10372 10381
16. Z. Chen, S.V. Sosnovtsev, K. Bok, G.I. Parra, M. Makiya, L. Agulto, K.Y. Green, and R.H. Purcell Development of Norwalk virus-specific monoclonal antibodies with therapeutic potential for the treatment of Norwalk virus gastroenteritis J. Virol. 87 2013 9547 9557
17. C. Conti, P. Mastromarino, P. Goldoni, G. Portalone, and N. Desideri Synthesis and anti-rhinovirus properties of fluoro-substituted flavonoids Antivir. Chem. Chemother. 16 2005 267 276
18. R.S. Choung, G.R. Locke 3rd, A.R. Zinsmeister, C.D. Schleck, and N.J. Talley Epidemiology of slow and fast colonic transit using a scale of stool form in a community Aliment. Pharmacol. Ther. 26 2007 1043 1050
19. V.P. Costantini, T. Whitaker, L. Barclay, D. Lee, T.R. McBrayer, R.F. Schinazi, and J. Vinje Antiviral activity of nucleoside analogues against Norovirus Antivir. Ther. 17 2012 981 991
20. De Clercq, E., in press. Dancing with chemical formulae of antivirals: a panoramic view (part 2). Biochem. Pharm. http://dx.doi.org/10.1016/j.bcp.2013. 09.010.
21. C. Deng, K. Hanna, V. Bril, M.C. Dalakas, P. Donofrio, P.A. van Doorn, H.P. Hartung, and I.S. Merkies Challenges of clinical trial design when there is lack of clinical equipoise: use of a response-conditional crossover design J. Neurol. 259 2012 348 352
22. E. Dicaprio, Y. Ma, J. Hughes, and J. Li Epidemiology, prevention, and control of the number one foodborne illness: human norovirus Infect. Dis. Clin. North Am. 27 2013 651 674
23. M. Doshi, S. Woodwell, K. Kelleher, K. Mangan, and P. Axelrod An outbreak of norovirus infection in a bone marrow transplant unit Am. J. Infect. Control 41 2013 820 823
24. D. Dou, S.R. Mandadapu, K.R. Alliston, Y. Kim, K.-O. Chang, and W.C. Groutas Design and synthesis of inhibitors of noroviruses by scaffold hopping Bioorg. Med. Chem. 19 2011 5749 5755
25. D. Dou, G. He, S.R. Mandadapu, S. Aravapalli, Y. Kim, K.-O. Chang, and W.C. Groutas Inhibition of noroviruses by piperazine derivatives Bioorg. Med. Chem. Lett. 22 2012 377 379
26. D. Dou, S.R. Mandadapu, K.R. Alliston, Y. Kim, K.-O. Chang, and W.C. Groutas Cyclosulfamide-based derivatives as inhibitors of noroviruses Eur. J. Med. Chem. 47 2012 59 64
27. D. Dou, K.-C. Tiew, S.R. Mandadapu, M.R. Gunnam, K.R. Alliston, Y. Kim, K.O. Chang, and W.C. Groutas Potent norovirus inhibitors based on the acyclic sulfamide scaffold Bioorg. Med. Chem. 20 2012 2111 2118
28. S. Esposito, B. Ascolese, L. Senatore, and C. Codecà Pediatric norovirus infection Eur. J. Clin. Microbiol. Infect. Dis. 33 2014 285 290
29. H. Fang, M. Tan, M. Xia, L. Wang, and X. Jiang Norovirus P particle efficiently elicits innate, humoral and cellular immunity PLoS One 8 2013 e63269
30. X. Feng, and X. Jiang Library screen for inhibitors targeting norovirus binding to histo-blood group antigen receptors Antimicrob. Agents Chemother. 51 2007 324 331
31. Y. Furuta, B.B. Gowen, K. Takahashi, K. Shiraki, D.F. Smee, and D.L. Barnard Favipiravir (T-705), a novel viral RNA polymerase inhibitor Antivir. Res. 100 2013 446 454
32. C. Gardelli, B. Attenni, M. Donghi, M. Meppen, B. Pacini, S. Harper, A. Di Marco, F. Fiore, C. Giuliano, V. Pucci, R. Laufer, N. Gennari, I. Marcucci, J.F. Leone, D.B. Olsen, M. MacCoss, M. Rowley, and F. Narjes Phosphoramidate prodrugs of 2′-C-methylcytidine for therapy of hepatitis C virus infection J. Med. Chem. 52 2009 5394 5407
33. P.A. Gastañaduy, A.J. Hall, A.T. Curns, U.D. Parashar, and B.A. Lopman Burden of norovirus gastroenteritis in the ambulatory setting - United States, 2001-2009 J. Infect. Dis. 207 2013 1058 1065
34. C. Gaulin, S. Nguon, M.A. Leblanc, D. Ramsay, and S. Roy Multiple outbreaks of gastroenteritis that were associated with 16 funerals and a unique caterer and spanned 6 days J. Food Prot. 76 2011 1582 1589
35. R.I. Glass, U.D. Parashar, and M.K. Estes Norovirus gastroenteritis N. Engl. J. Med. 361 2009 1776 1785
36. K.Y. Green Caliciviridae: the noroviruses D.M. Knipe, P. Howley, Fields Virology Sixth ed. 2013 Lippincott Williams & Wilkins Philadelphia 582 608
37. J.D. Greig, and M.B. Lee Enteric outbreaks in long-term care facilities and recommendations for prevention: a review Epidemiol. Infect. 137 2009 145 155
38. A.J. Hall, J. Vinjé, B. Lopman, G.W. Park, C. Yen, N. Gregoricus, and U. Parashar Updated norovirus outbreak management and disease prevention guidelines MMWR Recomm. Rep. 60 2011 1 18
39. A.J. Hall, B.A. Lopman, D.C. Payne, M.M. Patel, P.A. Gastañaduy, J. Vinjé, and U.D. Parashar Norovirus disease in the United States Emerg. Infect. Dis. 19 2013 1198 1205
40. A.J. Hall, M.E. Wikswo, K. Manikonda, V.A. Roberts, J.S. Yoder, and L.H. Gould Acute gastroenteritis surveillance through the National Outbreak Reporting System, United States Emerg. Infect. Dis. 19 2013 1305 1309
41. J.P. Harris, B.A. Lopman, B.S. Cooper, and S.J. O'Brien Does spatial proximity drive norovirus transmission during outbreaks in hospitals? BMJ Open 13 3 2013 e003060
42. M. Hassine-Zaafrane, K. Sdiri-Loulizi, J. Kaplon, I.B. Salem, P. Pothier, M. Aouni, and K. Ambert-Balay Prevalence and genetic diversity of norovirus infection in Tunisian children (2007-2010) J. Med. Virol. 85 2013 1100 1110
43. K. Higo-Moriguchi, H. Shirato, Y. Someya, Y. Kurosawa, N. Takeda, and K. Taniguchi Isolation of cross-reactive human monoclonal antibodies that prevent binding of human noroviruses to histo-blood group antigens J. Med. Virol. 86 2014 558 567
44. P. Huynen, A. Mauroy, C. Martin, L.G. Savadogo, R. Boreux, E. Thiry, P. Melin, and P. De Mol Molecular epidemiology of norovirus infections in symptomatic and asymptomatic children from Bobo Dioulasso, Burkina Faso J. Clin. Virol. 58 2013 515 521
45. M. Jin, Y. He, H. Li, P. Huang, W. Zhong, H. Yang, H. Zhang, M. Tan, and Z.J. Duan Two gastroenteritis outbreaks caused by GII Noroviruses: host susceptibility and HBGA phenotypes PLoS One 8 2013 e58605
46. K. Jung, Q. Wang, Y. Kim, K. Scheuer, Z. Zhang, Q. Shen, K.-O. Chang, and L.J. Saif The effect of simvastatin or interferon-α on infectivity of human Norovirus using a gnotobiotic pig model for the study of antivirals PLoS One 7 2012 e4619, 1-11
47. A.Z. Kapikian, M.K. Estes, and R.M. Channok Norwalk group of viruses B.N. Fields, D.M. Knipe, P. Howley, Fields Virology 1997 Lippincott-Raven Phil., PA, USA 783 810
48. S.S. Kaufman, N.K. Chatterjee, M.E. Fuschino, D.L. Morse, R.A. Morotti, M.S. Magid, G.E. Gondolesi, S.S. Florman, and T.M. Fishbein Characteristics of human Calicivirus enteritis in intestinal transplant recipients J. Pediatr. Gastroenterol. Nutr. 40 2005 328 333
49. Y. Kim, S. Lovell, K.-C. Tiew, S.R. Mandadapu, K.R. Alliston, K.P. Battaile, W.C. Groutas, and K.-O. Chang Broad-spectrum antivirals against 3C or 3C-like proteases of Picornaviruses, Noroviruses, and Coronaviruses J. Virol. 86 2012 11754 11762
50. H.L. Koo, F.H. Neill, M.K. Estes, F.M. Munoz, A. Cameron, H.L. Dupont, and R.L. Atmar Noroviruses: the most common pediatric viral enteric pathogen at a large university hospital after introduction of rotavirus vaccination J. Pediatr. Infect. Dis. Soc. 2 2013 57 60
51. C.N. Kotton CMV: prevention, diagnosis and therapy Am. J. Transplant. 13 Suppl. 3 2013 24 40
52. A. Kroneman, L. Verhoef, J. Harris, H. Vennema, E. Duizer, Y. van Duynhoven, J. Gray, M. Iturriza, B. Böttiger, G. Falkenhorst, C. Johnsen, C.H. von Bonsdorff, L. Maunula, M. Kuusi, P. Pothier, A. Gallay, E. Schreier, M. Höhne, J. Koch, G. Szücs, G. Reuter, K. Krisztalovics, M. Lynch, P. McKeown, B. Foley, S. Coughlan, F.M. Ruggeri, I. Di Bartolo, K. Vainio, E. Isakbaeva, M. Poljsak-Prijatelj, A.H. Grom, J.Z. Mijovski, A. Bosch, J. Buesa, A.S. Fauquier, G. Hernandéz-Pezzi, K.O. Hedlund, and M. Koopmans Analysis of integrated virological and epidemiological reports of norovirus outbreaks collected within the Foodborne Viruses in Europe network from 1 July 2001 to 30 June 2006 J. Clin. Microbiol. 46 2008 2959 2965
53. R.M. Lee, J. Lessler, R.A. Lee, K.E. Rudolph, N.G. Reich, T.M. Perl, and D.A. Cummings Incubation periods of viral gastroenteritis: a systematic review BMC Infect. Dis. 13 2013 446
54. J. Li, A. Predmore, E. Divers, and F. Lou New interventions against human Norovirus; progress, opportunities, and challenges Annu. Rev. Food Sci. Technol. 3 2012 331 352
55. L.C. Lindesmith, M. Beltramello, E.F. Donaldson, D. Corti, J. Swanstrom, K. Debbink, A. Lanzavecchia, and R.S. Baric Immunogenetic mechanisms driving norovirus GII.4 antigenic variation PLoS Pathog. 8 5 2012 e1002705
56. A. Ludwig, O. Adams, H.J. Laws, H. Schroten, and T. Tenenbaum Quantitative detection of norovirus excretion in pediatric patients with cancer and prolonged gastroenteritis and shedding of norovirus J. Med. Virol. 80 2008 1461 1467
57. S.R. Mandadapu, M.R. Gunnam, K.-C. Tiew, R.A.Z. Uy, A.M. Prior, K.R. Alliston, D.H. Hua, Y. Kim, K.-O. Chang, and W.C. Groutas Inhibition of norovirus 3CL protease by bisulfite adducts of transition state inhibitors Bioorg. Med. Chem. Lett. 23 2013 62 65
58. E. Mastrangelo, M. Pezzullo, D. Tarantino, R. Petazzi, F. Germani, D. Kramer, I. Robel, J. Rohayem, M. Bolognesi, and M. Milani Structure-based inhibition of Norovirus RNA-dependent RNA polymerases J. Mol. Biol. 419 2012 198 210
59. M.O. Milbrath, I.H. Spicknall, J.L. Zelner, C.L. Moe, and J.N. Eisenberg Heterogeneity in norovirus shedding duration affects community risk Epidemiol. Infect. 141 2013 1572 1584
60. S.G. Morillo, A. Luchs, A. Cilli, and M. do Carmo Sampaio Tavares Timenetsky Rapid detection of norovirus in naturally contaminated food: foodborne gastroenteritis outbreak on a cruise ship in Brazil, 2010 Food Environ. Virol. 4 2012 124 129
61. MMWR Norovirus outbreaks on three college campuses - California, Michigan, and Wisconsin, 2008 Morb. Mortal. Wkly Rep. 58 2009 1095 1100
62. G.W. Park, L. Barclay, D. Macinga, D. Charbonneau, C. Pettigrew, and J. Vinjé Comparative efficacy of seven hand sanitizers against murine Norovirus, feline Calicivirus, and GII.4 Norovirus J. Food Prot. 12 2010 2232 2238
63. J.W. Perry, M. Ahmed, K.O. Chang, N.J. Donato, H.D. Showalter, and C.E. Wobus Antiviral activity of a small molecule deubiquitinase inhibitor occurs via induction of the unfolded protein response PLoS Pathog. 8 7 2012 e1002783
64. C. Pierra, A. Amador, S. Benzaria, E. Cretton-Scott, M. D'Amours, J. Mao, S. Mathieu, A. Moussa, E.G. Bridges, D.N. Standring, J.P. Sommadossi, R. Storer, and G. Gosselin Synthesis and pharmacokinetics of valopicitabine (NM283), an efficient prodrug of the potent anti-HCV agent 2′-C- methylcytidine J. Med. Chem. 49 2006 6614 6620
65. M. Pieścik-Lech, R. Shamir, A. Guarino, and H. Szajewska Review article: the management of acute gastroenteritis in children Aliment. Pharmacol. Ther. 37 2013 289 303
66. L. Pokhrel, Y. Kim, T.D.T. Nguyen, A.M. Prior, J. Lu, K.-O. Chang, and D.H. Hua Synthesis and anti-norovirus activity of pyranobenzopyrone compounds Bioorg. Med. Chem. Lett. 22 2012 3480 3484
67. A.M. Prior, Y. Kim, S. Weerasekara, M. Moroze, K.R. Alliston, R.A.Z. Uy, W.C. Groutas, K.-O. Chang, and D.A. Hua Design, synthesis, and bioevaluation of viral 3C and 3C-like protease inhibitors Bioorg. Med. Chem. Lett. 23 2013 6317 6320
68. M.B. Reddy, P.N. Morcos, S. Le Pogam, Y. Ou, K. Frank, T. Lave, and P. Smith Pharmacokinetic/pharmacodynamic predictors of clinical potency for hepatitis C virus nonnucleoside polymerase and protease inhibitors Antimicrob. Agents Chemother. 56 2012 3144 3156
69. E. Rhinehart, S. Walker, D. Murphy, K. O'Reilly, and P. Leeman Frequency of outbreak investigations in US hospitals: results of a national survey of infection preventionists Am. J. Infect. Control 40 2012 2 8
70. J.D. Robles, D.K. Cheuk, S.Y. Ha, A.K. Chiang, and G.C. Chan Norovirus infection in pediatric hematopoietic stem cell transplantation recipients: incidence, risk factors, and outcome Biol. Blood Marrow Transplant. 18 2012 1883 1889
71. J. Rocha-Pereira, R. Cunha, D.C. Pinto, A.M. Silva, and M.S. Nascimento (E)-2-styrylchromones as potential anti-norovirus agents Bioorg. Med. Chem. 18 2010 4195 4201
72. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, M.S.J. Nascimento, and J. Neyts Favipiravir (T-705) inhibits in vitro Norovirus replication Biochem. Biophys. Res. Commun. 424 2012 777 780
73. J. Rocha-Pereira, D. Jochmans, K. Dallmeier, P. Leyssen, R. Cunha, I. Costa, M.S.J. Nascimento, and J. Neyts Inhibition of Norovirus replication by the nucleoside analogue 2′-C-methylcytidine Biochem. Biophys. Res. Commun. 427 2012 796 800
74. J. Rocha-Pereira, D. Jochmans, Y. Debing, E. Verbeken, M.S.J. Nascimento, and J. Neyts The viral polymerase inhibitor 2′-C-methylcytidine inhibits Norwalk virus replication and protects against Norovirus-induced diarrhea and mortality in a mouse model J. Virol. 87 2013 11798 11805
75. C. Roddie, J.P. Paul, R. Benjamin, C.I. Gallimore, J. Xerry, J.J. Gray, K.S. Peggs, E.C. Morris, K.J. Thomson, and K.N. Ward Allogeneic hematopoietic stem cell transplantation and norovirus gastroenteritis: a previously unrecognized cause of morbidity Clin. Infect. Dis. 49 2009 1061 1068
76. J. Rohayem, M. Bergmann, J. Gebhardt, E. Gould, P. Tucker, A. Mattevi, T. Unge, R. Hilgenfeld, and J. Neyts Antiviral strategies to control calicivirus infections Antivir. Res. 87 2010 162 178
77. D. Roos-Weil, K. Ambert-Balay, F. Lanternier, M.F. Mamzer-Bruneel, D. Nochy, P. Pothier, V. Avettand-Fenoel, D. Anglicheau, R. Snanoudj, L. Bererhi, E. Thervet, M. Lecuit, C. Legendre, O. Lortholary, and J. Zuber Impact of norovirus/sapovirus-related diarrhea in renal transplant recipients hospitalized for diarrhea Transplantation 92 2011 61 69
78. J.F. Rossignol, and Y.M. El-Gohary Nitazoxanide in the treatment of viral gastroenteritis: a randomized double-blind placebo-controlled clinical trial Aliment. Pharmacol. Ther. 24 2006 1423 1430
79. J.F. Rossignol, M. Abu-Zekry, A. Hussein, and M.G. Santoro Effect of nitazoxanide for treatment of severe rotavirus diarrhoea: randomised double-blind placebo-controlled trial Lancet 368 2006 124 129
80. M.A. Saif, D.K. Bonney, B. Bigger, L. Forsythe, N. Williams, J. Page, Z.O. Babiker, M. Guiver, A.J. Turner, S. Hughes, and R.F. Wynn Chronic norovirus infection in pediatric hematopoietic stem cell transplant recipients: a cause of prolonged intestinal failure requiring intensive nutritional support Pediatr. Transplant. 15 2011 505 509
81. E. Scallan, R.M. Hoekstra, F.J. Angulo, R.V. Tauxe, M.A. Widdowson, S.L. Roy, J.L. Jones, and P.M. Griffin Foodborne illness acquired in the United States - major pathogens Emerg. Infect. Dis. 17 2011 7 15
82. R. Schorn, M. Höhne, A. Meerbach, W. Bossart, R.P. Wüthrich, E. Schreier, N.J. Müller, and T. Fehr Chronic norovirus infection after kidney transplantation: molecular evidence for immune-driven viral evolution Clin. Infect. Dis. 51 2010 307 314
83. S. Schwartz, M. Vergoulidou, E. Schreier, C. Loddenkemper, M. Reinwald, M. Schmidt-Hieber, W.A. Flegel, E. Thiel, and T. Schneider Norovirus gastroenteritis causes severe and lethal complications after chemotherapy and hematopoietic stem cell transplantation Blood 2 117 2011 5850 5856
84. S.R. Seitz, J.S. Leon, K.J. Schwab, G.M. Lyon, M. Dowd, M. McDaniels, G. Abdulhafid, M.L. Fernandez, L.C. Lindesmith, R.S. Baric, and C.L. Moe Norovirus infectivity in humans and persistence in water Appl. Environ. Microbiol. 77 2009 6884 6888
85. D.M. Siddiq, H.L. Koo, J.A. Adachi, and G.M. Viola Norovirus gastroenteritis successfully treated with nitazoxanide J. Infect. 63 2011 394 397
86. J.J. Siebenga, M.F. Beersma, H. Vennema, P. van Biezen, N.J. Hartwig, and M. Koopmans High prevalence of prolonged norovirus shedding and illness among hospitalized patients: a model for in vivo molecular evolution J. Infect. Dis. 198 2008 994 1001
87. A. Simon, O. Schildgen, A. Maria Eis-Hübinger, C. Hasan, U. Bode, S. Buderus, S. Engelhart, and G. Fleischhack Norovirus outbreak in a pediatric oncology unit Scand. J. Gastroenterol. 41 2006 693 699
88. C.W. So, D.S. Kim, S.T. Yu, J.H. Cho, and J.D. Kim Acute viral gastroenteritis in children hospitalized in Iksan, Korea during December 2010-June 2011 Korean J. Pediatr. 56 2013 383 388
89. F.H. Sukhrie, P. Teunis, H. Vennema, C. Copra, M.F. Thijs Beersma, J. Bogerman, and M. Koopmans Nosocomial transmission of norovirus is mainly caused by symptomatic cases Clin. Infect. Dis. 54 2012 931 937
90. M. Tan, and X. Jiang Norovirus-host interaction: implications for disease control and prevention Expert Rev. Mol. Med. 9 2007 1 22
91. M. Tan, and X. Jiang Norovirus gastroenteritis, carbohydrate receptors, and animal models PLoS Pathog. 6 2010 e1000983
92. D. Takahashi, Y. Kima, S. Lovell, O. Prakash, W.C. Groutas, and K.-O. Chang Structural and inhibitor studies of norovirus 3C-like proteases Virus Res. 178 2013 437 444
93. D. Tarantino, M. Pezzullo, E. Mastrangelo, R. Croci, J. Rohayem, I. Robel, M. Bolognesi, and M. Milani Naphthalene-sulfonate inhibitors of human norovirus RNA-dependent RNA-polymerase Antiviral Res. 102 2014 23 28
94. S. Taube, A.O. Kolawole, M. Höhne, J.E. Wilkinson, S.A. Handley, J.W. Perry, L.B. Thackray, R. Akkina, and C.E. Wobus A mouse model for human norovirus MBio 4 4 2013 i:e00450-13
95. V.T. Tomov, L.C. Osborne, D.V. Dolfi, G.F. Sonnenberg, L.A. Monticelli, K. Mansfield, H.W. Virgin, D. Artis, and E.J. Wherry Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses J. Virol. 87 2013 7015 7031
96. P.F. Teunis, C.L. Moe, P. Liu, S.E. Miller, L. Lindesmith, R.S. Baric, J. Le Pendu, and R.L. Calderon Norwalk virus: how infectious is it? J. Med. Virol. 80 2008 1468 1476
97. T.K. Trivedi, R. Desai, A.J. Hall, M. Patel, U.D. Parashar, and B.A. Lopman Clinical characteristics of norovirus-associated deaths: a systematic literature review Am. J. Infect. Control 41 2013 654 657
98. E. van der Vries, K.J. Stittelaar, G. van Amerongen, E.J. Veldhuis Kroeze, L. de Waal, P.L. Fraaij, R.J. Meesters, T.M. Luider, B. van der Nagel, B. Koch, A.G. Vulto, M. Schutten, and A.D. Osterhaus Prolonged influenza virus shedding and emergence of antiviral resistance in immunocompromised patients and ferrets PLoS Pathog. 9 2013 e1003343
99. J. Vermehren, and C. Sarrazin The role of resistance in HCV treatment Best Pract. Res. Clin. Gastroenterol. 26 2012 487 503
100. P. Viswanathan, J. May, S. Uhm, C. Yon, and B. Korba RNA binding by human Norovirus 3C-like proteases inhibits protease activity Virology 438 2013 20 27
101. S. Yamazaki, H. Nakamura, S. Yamagata, G. Miura, N. Hattori, K. Shinozaki, T. Sadahiro, A. Toyoda, H. Nakasa, N. Ariyoshi, S. Oda, K. Harigaya, and M. Kitada Unexpected serum level of vancomycin after oral administration in a patient with severe colitis and renal insufficiency Int. J. Clin. Pharmacol. Ther. 47 2009 701 706
102. D.F. Zamyatkin, F. Parra, J.M.M. Alonso, D.A. Harki, B.R. Peterson, P. Grochulski, and K.K.-S. Ng Structural insights into mechanisms of catalysis and inhibition in Norwalk virus polymerase JBC 283 2008 7705 7712
103. D.F. Zamyatkin, F. Parra, A. Machin, P. Grochulski, and K.K.-S. Ng Binding of 2′-amino-2′-deoxycytidine-5′-triphosphate to Norovirus polymerase induces rearrangement of the active site J. Mol. Biol. 390 2009 10 16
104. J.L. Zelner, B.A. Lopman, A.J. Hall, S. Ballesteros, and B.T. Grenfell Linking time-varying symptomatology and intensity of infectiousness to patterns of Norovirus transmission PLoS One 8 7 2013 e68413
105. X.F. Zhang, M. Tan, M. Chhabra, Y.C. Dai, J. Meller, and X. Jiang Inhibition of histo-blood group antigen binding as a novel strategy to block norovirus infections PLoS One 8 7 2013 e69379
106. S. Zhu, D. Regev, M. Watanabe, D. Hickman, N. Moussatche, D.M. Jesus, S.M. Kahan, S. Napthine, I. Brierley, R.N. Hunter 3rd, D. Devabhaktuni, M.K. Jones, and S.M. Karst Identification of immune and viral correlates of norovirus protective immunity through comparative study of intra-cluster norovirus strains PLoS Pathog. 9 9 2013 e1003592